Steven Pfanstiel compensation by year
MARINUS PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $420,000 | $470,000 |
| Stock awards | $209,434 | $167,092 |
| Option awards | $644,188 | $607,608 |
| Non-equity incentive | $151,200 | $190,350 |
| All other | $9,150 | $9,900 |
| Total | $1,433,972 | $1,444,950 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MARINUS PHARMACEUTICALS, INC. DEF 14A filed April 4, 2024, accession 0001558370-24-004691, and prior-year filings. Open the filing on EDGAR.
How this page was built: the MARINUS PHARMACEUTICALS, INC. filed document, accession 0001558370-24-004691. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 28,130 | $305,773 | — |
| RSU | 11,034 | $119,940 | — |
| RSU | 3,724 | $40,480 | — |
| Option | 87,898 | — | $5.94 |
| Option | 73,320 | — | $13.99 |
| Option | 28,957 | — | $10.40 |
Per the Outstanding Equity Awards at Fiscal Year-End table in MARINUS PHARMACEUTICALS, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2023 proxy (filed April 4, 2024)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-02-11 | Disposition to the issuer derivative | — | 220,000 | $0.00 | 0 |
| 2025-02-11 | Disposition to the issuer derivative | — | 57,300 | $0.00 | 0 |
| 2025-02-11 | Disposition to the issuer derivative | — | 74,475 | $0.00 | 0 |
| 2025-02-11 | Disposition to the issuer derivative | — | 126,585 | $0.00 | 0 |
| 2025-02-11 | Disposition to the issuer | — | 62,470 | $0.55 | 0 |
| 2025-02-11 | Disposition to the issuer derivative | — | 114,600 | $0.00 | 0 |
| 2025-02-07 | Disposition to the issuer | — | 17,303 | $0.55 | 62,470 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
MARINUS PHARMACEUTICALS’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Scott Braunstein | President, Chief Executive Officer and Director | $3,214,100 |
| Steven Pfanstiel · this page | Chief Operating Officer, Chief Financial Officer and Treasurer | $1,444,950 |
| Joseph Hulihan | Chief Medical Officer | $1,371,829 |
Steven Pfanstiel's compensation dossier, MARINUS PHARMACEUTICALS
You have read Steven Pfanstiel's totals and holdings. The dossier adds each equity grant MARINUS PHARMACEUTICALS disclosed for Steven Pfanstiel and MARINUS PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full MARINUS PHARMACEUTICALS compensation record
free company briefThis page is one person within MARINUS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the MARINUS PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MARINUS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.